Lower-dose chemo plus 14 days of blinatumomab for new B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 15 and 65 years old.
- You have been newly diagnosed with B-ALL and have not yet started treatment for it.
- Your leukemia is Philadelphia chromosome negative (a specific genetic marker).
- You are generally able to care for yourself (ECOG performance status 0-2).
- Your liver, kidney, and heart function are within acceptable limits.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This study tests a combination of a lower-dose chemotherapy and a short course of an immunotherapy drug called blinatumomab, before a stem cell transplant, to see if it helps improve outcomes for adults with certain types of ALL.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Hear when a new Leukemia, Lymphocytic, Acute, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.